Original language | English (US) |
---|---|
Pages (from-to) | 955-956 |
Number of pages | 2 |
Journal | Mayo Clinic Proceedings |
Volume | 93 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2018 |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome. / Silber, Michael H.; Becker, Philip M.; Buchfuhrer, Mark J. et al.
In: Mayo Clinic Proceedings, Vol. 93, No. 7, 07.2018, p. 955-956.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome
AU - Silber, Michael H.
AU - Becker, Philip M.
AU - Buchfuhrer, Mark J.
AU - Earley, Christopher J.
AU - Ondo, William G.
AU - Walters, Arthur S.
AU - Winkelman, John W.
N1 - Funding Information: Potential Competing Interests: Dr Silber receives royalties from UpToDate and payment for development of educational presentations from the American Academy of Sleep Medicine and American Academy of Neurology. Dr Buchfuhrer receives consultancy fees from Xenoport; receives payment for lectures including service on speakers bureaus from UCB Pharma, Arbor Pharmaceuticals, and Xenoport; owns stock/stock options in Sensory Medical. Dr Earley receives grants from Luitpold Pharmaceuticals and honorarium from the American Academy of Sleep Medicine. Dr Ondo receives grants from Luitpold Pharmaceuticals and payment for lectures including service on speakers bureaus from UCB Pharma. Dr Walters receives grants from Mundipharma, Arbor Pharmaceuticals, National Institutes of Health, UCB Pharma, and Xenoport. Dr Winkelman receives consultancy fees from Merck and Flex Pharma and grants from Restless Legs Syndrome Foundation, Luitpold Pharmaceuticals, NeuroMetrix, National Institute of Mental Health, and UCB Pharma; he is an employee of Massachusetts General Hospital. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/7
Y1 - 2018/7
UR - http://www.scopus.com/inward/record.url?scp=85048960397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048960397&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.03.021
DO - 10.1016/j.mayocp.2018.03.021
M3 - Letter
C2 - 29976378
AN - SCOPUS:85048960397
VL - 93
SP - 955
EP - 956
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 7
ER -